Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity.
about
Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancerKinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)X-ray structural studies of quinone reductase 2 nanomolar range inhibitorsIn Silico Screening Reveals Structurally Diverse, Nanomolar Inhibitors of NQO2 That Are Functionally Active in Cells and Can Modulate NF- B SignalingCrystal structure of quinone reductase 2 in complex with resveratrolRegulation of Nrf2-an updateIsolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata.Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors.Chloroquine binding reveals flavin redox switch function of quinone reductase 2.Bioactive compounds from the fern Lepisorus contortusNRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomasCircadian rhythms, oxidative stress, and antioxidative defense mechanisms.Pleiotropic mechanisms facilitated by resveratrol and its metabolites.Therapeutic potential of melatonin ligands.Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?Resveratrol: Biological and pharmaceutical properties as anticancer molecule.Quinone reductase 2 is a catechol quinone reductaseNRH:quinone oxidoreductase 2 (NQO2) protein competes with the 20 S proteasome to stabilize transcription factor CCAAT enhancer-binding protein α (C/EBPα), leading to protection against γ radiation-induced myeloproliferative disease.Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling.Quinone reductase 2 as a promising target of melatonin therapeutic actions.Non-kinase targets of protein kinase inhibitors.r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.Melatonin inhibits granulocyte adhesion to ICAM via MT3/QR2 and MT2 receptors.NQO2 is a reactive oxygen species generating off-target for acetaminophen.The antidote effect of quinone oxidoreductase 2 inhibitor against paraquat-induced toxicity in vitro and in vivo.Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).
P2860
Q24305235-26FE8D7C-E9DB-4917-8F83-7C58E05DD2C3Q27649797-B77104F1-9239-4B67-9B13-DB123FE035C2Q27653890-504EF7BE-41D0-4890-9281-5319E8A2CB30Q27667662-64E170B2-3091-4BA9-BEEC-90AE359F8E21Q27675614-D398130A-3EFE-4BF1-AA79-AA52CA2BA920Q28280502-D6C28725-8279-461A-9BE7-96AAEB98C465Q28388589-8E483CAE-473B-4BE9-B58A-4BA4BDD7EEDFQ33837074-D100BA03-A77D-4AA8-999D-3B60D3F0071CQ34146957-A0CDDAAC-3077-4E68-B944-BAE258B61AD1Q34331796-FDA3AA2E-310C-44EA-91F8-AD9C2F7831D8Q34749866-4134AD18-70CB-4CCC-8C77-8128D6335DE2Q35055410-FA343ECE-14D2-4692-8992-8370D8F2440DQ35609478-F35B9744-EA69-411C-BF79-47BEE53EDCADQ35692517-4C3124D3-BFFD-41F7-B899-3788DC30DE22Q36474524-35BA3A53-741E-4F2F-B011-B802F807FBF7Q36790172-35CBEDD3-E999-4881-B987-A1E9384B7E49Q36848141-5687CE0F-A6A4-46CE-81DA-AE0C4F861AC0Q36856168-7C2DBD24-D6A3-4934-8FA2-9C2B9E375516Q37348985-DEC16B78-3F09-4C4B-8EFB-04229ACC3223Q37950409-FC7DC794-2A8E-4A0B-BE94-4A39BB66F195Q38606734-9920F531-7952-4338-A9BF-80599877EF01Q39171961-B141C509-7F08-405E-B79A-4EEDD0CD627FQ40288458-FA2C4925-8E12-4401-9A31-C6746D0BF441Q40296515-3032C7DB-2416-4F57-966F-461DC2B60BB0Q41192507-AC8B5DC8-0207-45E5-AD48-D82EFAD75877Q41948906-968E9368-05D3-488D-81AD-7258E63FBEFAQ42253314-ACA7E201-F26B-4E89-B7C4-4052002DA1C9Q44760560-78B2EA95-C9F9-467D-B48B-995E1F95AD5EQ45175176-B7C93CF5-567C-4FF0-8324-41CD91F0859FQ47251583-B6F8A204-5473-4E5A-B38D-F9B0084C8885Q50770722-D3D3A0D0-1A2D-44D1-99D4-B0B935246A8C
P2860
Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Disruption of dihydronicotinam ...... itivity to menadione toxicity.
@en
Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2
@nl
type
label
Disruption of dihydronicotinam ...... itivity to menadione toxicity.
@en
Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2
@nl
prefLabel
Disruption of dihydronicotinam ...... itivity to menadione toxicity.
@en
Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2
@nl
P2093
P2860
P356
P1476
Disruption of dihydronicotinam ...... itivity to menadione toxicity.
@en
P2093
Amos Gaikwad
Anil K Jaiswal
Delwin J Long
Dennis R Roop
Karim Iskander
Meral Arin
Richard Knox
Roberto Barrios
P2860
P304
46131-46139
P356
10.1074/JBC.M208675200
P407
P577
2002-09-25T00:00:00Z